An extensive review of this topic [6] suggested that a retarding effect of ACEI on the progression of chronic, nondiabetic human renal failure, as postulated by other groups [ 1 ‚ 2], is far from being clearly demonstrated. Conversely, in another study performed in diabetics [2] , it was claimed that captopril delayed the progression of renal failure, even though the percentages of patients needing renal replacement therapy at the end of the observation period in both placebo (15.34%) and captopril (9.66%) groups were not significantly different (p = 0.11 ‚ two-tailed chisquare test with the Yates correction; 95% confidence interval -0.006, < 0.05, < 0.12 NS). So far, these considerations, in addition to our disappointing observations, suggest Systolic blood pressure, mm Hg 161.11.5 153 ± 13.0 161. ± 9.0 A vs. B NS Avs.CNS Diastolic blood pressure, mm Hg 87 ± 5.4 82 ± 6.0 85 ± 6.0 B vs. C NS Analysis was performed using the two-tailed Bonferroni method with multiple comparisons. that the beneficial effects of ACEI in delaying the progression of kidney dysfunction have not yet been proved and that their use in diabetic or nondiabetic patients with chronic renal disease carries the risk of precipitating further renal deterioration.
